A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: Evidence of efficacy continues to mount
- 31 October 2010
- journal article
- other
- Published by Elsevier BV in Leukemia Research
- Vol. 34 (10), e268-e269
- https://doi.org/10.1016/j.leukres.2010.03.046
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLBlood, 2010
- Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantationBlood, 2009
- Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapyEuropean Journal of Cancer and Clinical Oncology, 1985